PCSK9 and inherited lipid metabolism disorder: In second place in the treatment of dyslipidaemia are currently the PCSK9 inhibitors—alirocumab, evolocumab, and inclisiran, which is not strictly a PCSK9 inhibitor, but is often included in the same group of drugs.